Aduro Announces Presentations at the Upcoming BIO CEO and Investor Conference and Leerink Global Healthcare Conference

Leerink Global Healthcare Conference 2014

BERKELEY, Calif.--()--Aduro BioTech, Inc., a clinical stage biotechnology company, today announced that the company’s chairman and chief executive officer, Stephen T. Isaacs, will present a company overview at the following upcoming conferences:

  • BIO CEO and Investor Conference, February 11 at 9:30 a.m. ET, New York
  • Leerink Global Healthcare Conference, February 12 at 8:00 a.m. ET, New York

To access the live webcast and subsequent archived recording of the BIO CEO and Investor Conference presentation, please visit the company’s website at www.adurobiotech.com

About Aduro BioTech, Inc.

Aduro BioTech, Inc. is a clinical-stage biotechnology company focused on immunotherapy for cancer. Aduro has ongoing clinical development programs in pancreatic cancer, mesothelioma and glioblastoma. The company is also developing clinical candidates that utilize small molecules that activate STING (stimulator of interferon genes), a central mediator of the innate immune response. The company’s pipeline also includes programs in non-small-cell lung cancer, ovarian cancer and prostate cancer. For more information, please visit www.adurobiotech.com.

Contacts

Aduro BioTech, Inc.
Greg Schafer, 510-809-4801
Chief Operating Officer

Contacts

Aduro BioTech, Inc.
Greg Schafer, 510-809-4801
Chief Operating Officer